NYSE: ANROAlto Neuroscience Inc Stock
$11.96-0.04 (-0.33%)
Updated May 31, 2024
ANRO Price
$11.96
Fair Value Price
N/A
Market Cap
$321.53M
52 Week Low
$11.68
52 Week High
$24.00
P/E
N/A
P/B
1.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
N/A
Beta
-0.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANRO is good value based on its book value relative to its share price (1.67x), compared to the US Biotechnology industry average (6.04x)
P/B vs Industry Valuation
ANRO's short-term assets ($208.31M) exceed its short-term liabilities ($8.01M)
Short-term Liabilities Financials
ANRO's short-term assets ($208.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more ANRO due diligence checks available for Premium users.
Be the first to know about important ANRO news, forecast changes, insider trades & much more!
ANRO News
Valuation
ANRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
6.04x
ANRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANRO's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.4M
Profit Margin
0%
Assets to liabilities
Assets
$209.9M
Liabilities
$16.8M
Debt to equity
0.09
ANRO's short-term assets ($208.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANRO's short-term assets ($208.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
-$224.0k
Financing
$134.6M
ANRO vs Biotech Stocks
Alto Neuroscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.